MedTrace Logo

An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia

NCT00485615 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-10-30

No results posted yet for this study

Summary

The primary objective is to evaluate the efficacy of an enteric-coated, eicosapentaenoic acid-concentrated fish oil in the treatment of social phobia. A secondary objective is to determine if treatment outcome is related to plasma phospholipid essential fatty acid status, niacin skin flush and measures of lipid/protein peroxidation.

Conditions

Interventions

DRUG

Omega 3 Joy enteric coated concentrated fish oil

1500-3000mg; one per day

Sponsors & Collaborators

  • Genuine Health

    collaborator INDUSTRY

  • START Clinic for Mood and Anxiety Disorders

    lead OTHER

Principal Investigators

  • Martin A. Katzman, MD · START Clinic for Mood and Anxiety Disorders

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00485615 on ClinicalTrials.gov